EZH2 and breast carcinoma: A peptide nucleic acid (PNA)-based approach was reported to block the EZH2-binding domain of HOTAIR, inhibiting HOTAIR-EZH2 activity and subsequently decreasing invasion of ovarian and breast cancer cells and resensitizing resistant ovarian tumors to platinum-based chemotherapy (Özeş et al., 2017).